High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

Pan, J; Yang, J F; Deng, B P; Zhao, X J; Zhang, X; Lin, Y H; Wu, Y N; Deng, Z L; Zhang, Y L; Liu, S H; Wu, T; Lu, P H; Lu, D P; Chang, A H; Tong, C R

Pan, J; Yang, J F; Deng, B P; Zhao, X J; Zhang, X; Lin, Y H; Wu, Y N; Deng, Z L; Zhang, Y L; Liu, S H; Wu, T; Lu, P H; Lu, D P; Chang, A H; Tong, C R.

Afiliação

Pan J; Department of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Yang JF; Department of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Deng BP; Department of Immunotherapy, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Zhao XJ; Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Zhang X; Department of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Lin YH; Department of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Wu YN; Department of Immunotherapy, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Deng ZL; Department of Immunotherapy, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Zhang YL; Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Liu SH; Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Wu T; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Lu PH; Department of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Lu DP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Chang AH; Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Tong CR; Department of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.

Leukemia ; 31(12): 2587-2593, 2017 12.

Article em En | MEDLINE | ID: mdl-28490811

Assuntos

Antígenos CD19/imunologia; Imunoterapia Adotiva; Leucemia-Linfoma Linfoblástico de Células Precursoras B/imunologia; Leucemia-Linfoma Linfoblástico de Células Precursoras B/terapia; Especificidade do Receptor de Antígeno de Linfócitos T/imunologia; Linfócitos T/imunologia; Linfócitos T/metabolismo; Adolescente; Adulto; Animais; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Criança; Pré-Escolar; Estudos de Coortes; Terapia Combinada/métodos; Modelos Animais de Doenças; Resistencia a Medicamentos Antineoplásicos; Feminino; Transplante de Células-Tronco Hematopoéticas/efeitos adversos; Transplante de Células-Tronco Hematopoéticas/métodos; Xenoenxertos; Humanos; Imunoterapia Adotiva/efeitos adversos; Imunoterapia Adotiva/métodos; Masculino; Camundongos; Leucemia-Linfoma Linfoblástico de Células Precursoras B/diagnóstico; Leucemia-Linfoma Linfoblástico de Células Precursoras B/mortalidade; Recidiva; Especificidade do Receptor de Antígeno de Linfócitos T/genética; Resultado do Tratamento; Adulto Jovem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Leucemia-Linfoma Linfoblástico de Células Precursoras B / Imunoterapia Adotiva / Antígenos CD19 / Especificidade do Receptor de Antígeno de Linfócitos T Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google